News & Resources

Published On 11 February

Invitrocue creates Joint Venture with A*STAR scientist Dr. Chen Qingfeng

EXCERPT:  February 11, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the establishment of InvivoCue, a joint venture (JV) between Invitrocue and A*STAR scientist Dr. Chen Qingfeng. Invitrocue will own 70% of the Company, while Dr Chen will own 30%. The JV will supply humanised immune system […]

Learn more
Published On 01 February

Quarterly Appendix 4C and Business updates

Quarterly Appendix 4C and Business updates

Learn more
Published On 23 January

IVQ technology development agreement with SIBCB on breast cancer.

EXCERPT: January 23, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the signing of a new technology development agreement with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences, for the laboratory culture and development of new breast cancer models for Invitrocue’s proprietary Onco-PDOTM […]

Learn more
Published On 21 January

Invitrocue roll-out of Onco-PDO services in Germany

EXCERPT: “We are pleased to establish Invitrocue’s first laboratory in Europe, quickly expanding the availability of Onco-PDOTM to a much wider patient and physician group. Approximately one quarter of the global total of cancer cases are in Europe with some 3.7 million new patients a year. Our collaboration with Systasy enables us to deliver against […]

Learn more
Published On 15 January

Invitrocue Appoints Renowned Oncology Researcher Professor Jesús García-Foncillas as Clinical Advisor

EXCERPT:  January 15, 2019 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Jesús García-Foncillas as Clinical Advisor of Invitrocue. Professor Jesús is an experienced oncology researcher with 25 years of experience in cancer diagnosis and treatment. He holds multiple executive leadership positions at “Fundacion […]

Learn more
Published On 15 January

Expiry of unlisted options – Jan 2019

Expiry of Unlisted Options

Learn more
Published On 11 January

Final Director’s Interest Notice

Final Director’s Interest Notice

Learn more
Published On 11 January

Invitrocue Appoints Professor Masakazu Toi as Clinical Advisor

EXCERPT: January 11, 2019 – Invitrocue Limited (ASX: IVQ), a leader healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Masakazu Toi as Clinical Advisor of Invitrocue. A renowned oncology expert having held various roles as healthcare provider, scholar, and opinion leader, Professor Toi brings strong clinical oncology knowledge and experience especially […]

Learn more
Published On 09 January

Invitrocue announced Board Changes

EXCERPT: January 9, 2019 – Invitrocue Limited (ASX : IVQ), a leading healthcare bio-analytic solutions provider, announces the appointment of Dr. Steven Fang as Chairman of the Company’s Board of Directors with immediate effect. Dr. Fang is a co-founder and the Executive Director of Invitrocue with more than 20 years’ experience in leading and building successful […]

Learn more
Published On 27 December

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more